Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Return on Equity (2021 - 2025)

Historic Return on Equity for Barinthus Biotherapeutics (BRNS) over the last 5 years, with Q3 2025 value amounting to 0.81%.

  • Barinthus Biotherapeutics' Return on Equity fell 4500.0% to 0.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.81%, marking a year-over-year decrease of 4500.0%. This contributed to the annual value of 0.39% for FY2024, which is 400.0% down from last year.
  • As of Q3 2025, Barinthus Biotherapeutics' Return on Equity stood at 0.81%, which was down 4500.0% from 0.64% recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Return on Equity peaked at 0.62% during Q1 2021, and registered a low of 0.81% during Q3 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' median Return on Equity value was 0.37% (recorded in 2024), while the average stood at 0.26%.
  • Over the last 5 years, Barinthus Biotherapeutics' Return on Equity had its largest YoY gain of 3900bps in 2022, and its largest YoY loss of -7600bps in 2022.
  • Over the past 5 years, Barinthus Biotherapeutics' Return on Equity (Quarter) stood at 0.19% in 2021, then skyrocketed by 111bps to 0.02% in 2022, then plummeted by -1858bps to 0.38% in 2023, then fell by -10bps to 0.42% in 2024, then plummeted by -92bps to 0.81% in 2025.
  • Its last three reported values are 0.81% in Q3 2025, 0.64% for Q2 2025, and 0.53% during Q1 2025.